Medtronic CEO Omar Ishrak tells MassDevice.com that medtech must embrace value-based healthcare if it wants to escape the death spiral of commoditization.
St. Jude Medical president & CEO Dan Starks says that rival Medtronic’s failed renal denervation study is no reason to stop pursuing the technology in treatment of hypertension.
Boston Scientific CEO Mike Mahoney says the company is still bullish on the prospects for its Vessix renal denervation platform for treating high blood pressure, despite the efficacy failure of Medtronic’s gold-standard Symplicity HTN-3 trial.
Intuitive Surgical president & CEO Gary Guthart says that hospitals are "absorbing" the message that, despite the headline-grabbing commotion over adverse events, da Vinci is still far safer than open surgery.
Edwards Lifesciences CEO Michael Mussallem promises to make aggressive moves in defending its territory in the transcatheter aortic valve implantation market.
Covidien CEO José Almeida says the medical device company is willing to pull resources from its businesses in the U.S. and Europe to bolster its footprint in emerging markets.
Thoratec president & CEO Gary Burbach says that survival and adverse event rates associated with the company’s HeartMate II LVAD have improved significantly compared to what was reported in a New England Journal of Medicine article late last year.